An assay quantifying the loss of antibacterial potency of compounds, originally identified via target-based screening, in the presence of increasing albumin concentration was developed and used as a technique to measure potential association of compounds with proteins unrelated to their molecular target. Minimum inhibitory concentrations (MICs) of test compounds were measured against Staphylococcus aureus strain ATCC 6538 in the presence of 0-12 µM bovine serum albumin (BSA). The linear regression coefficient r 2 for the correlation between MIC and BSA concentration was ≥ 0.9 for 49 and > 0.5 for 62 out of a total of 69 compounds tested. The slope of these correlations varied widely from < 1 to 99, suggesting that the loss of potency due to a given concentration of BSA could vary from compound to compound due to wide variation in the apparent stoichiometry for protein-ligand association. Follow-up experiments using additional proteins and a fatty acid, oleic acid, showed that this compound:BSA association was not protein specific, but was likely driven by hydrophobicity. The method described in this report can be used to optimize compound design and minimize this undesirable effect. (Journal of Biomolecular Screening 2003:555-558) 
INTRODUCTION
H IGH-THROUGHPUT SCREENING (HTS) is frequently used in antibacterial drug discovery to identify hits, which inhibit various biological functions, such as activities of essential enzymes and proteins involved in biosynthetic pathways, thereby inhibiting growth of whole-cell bacteria. 1 However, a number of HTS hits identified by screening also exhibit nonspecific mechanisms involving inhibition of multiple molecular targets and metabolic pathways, leading to whole-cell bacterial growth inhibition. 2 Consequently, it becomes difficult to differentiate the desired, mechanism-based effect from the unintended, nonspecific effects. This presents a major challenge for further optimization of hit po-tency via structure-activity relationship (SAR) studies. Recently, several observations that could suggest mechanistic nonspecificity of hits have been described in the literature. [2] [3] [4] These qualitative observations include a) comparable inhibition potencies against multiple, structurally or mechanistically unrelated molecular targets; b) hydrophobic interaction with macromolecules, including lipids; and c) loss of hit potency due to increased protein concentration. However, a simple method to measure the extent of nonspecific association with macromolecules could be useful as a tool to minimize this undesirable effect in successive rounds of compound optimization.
Recently, in a target-based antibacterial discovery program, a set of compounds were identified via HTS as inhibitors of Penicillin-Binding Proteins 2x and 2a (PBP 2x and PBP 2a), cloned from penicillin-resistant Streptococcus pneumoniae and methicillinresistant Staphylococcus aureus, respectively. Original hits with inhibitory activity against the PBPs were further optimized via SAR studies. This approach led to compounds with inhibitory activities against both the PBPs as well as antibacterial activity against gram-positive pathogens. However, initial compounds lost antibacterial activity in the presence of serum or albumin at concentrations far below physiological levels. This loss of activity could not be attributed to the site-specific albumin binding that represents a pharmacological challenge for certain classes of antibac-terial drugs, including β-lactams. 5 To better understand the phenomenon and optimize compound design, a simple assay was developed to measure the stoichiometry of compound:protein association, using the minimum inhibitory concentrations (MICs) of test compounds in the presence of variable concentrations of bovine serum albumin (BSA).
MATERIALS AND METHODS
Test compounds were synthesized at Procter & Gamble Pharmaceuticals (Mason, OH). Penicillin, used as benchmark, BSA, and human serum albumin (HSA) were purchased from Sigma Aldrich (St. Louis, MO). MICs were determined against S. aureus strain ATCC 6538 grown in brain heart infusion (BHI) broth containing 2% dimethyl sufloxide (DMSO) in U-bottom, 96-well plates (FALCON ® ; Becton Dickinson and Co., Franklin Lakes, NJ), using a 2-fold serial dilution of the test compounds or penicillin (benchmark) following established procedure. 6 Test compounds were first dissolved in DMSO. Presence of DMSO in the assay broth was necessary to keep the test inhibitors in solution. Each plate contained control wells containing no inhibitor. The MIC of the test compound or the benchmark was defined as the concentration at which bacterial growth was completely inhibited (as judged by visual inspection of the well). Results from each plate were validated based on the accurate determination of the MIC for penicillin. To measure the effects of BSA, yeast alcohol dehydrogenase (ALDH), soybean trypsin inhibitor (TI), and oleic acid (from Sigma Aldrich), MICs of the test compound and penicillin were determined in presence of varying concentrations of these agents. Stock solutions of BSA, ALDH, and TI were made in BHI broth and were diluted to achieve the desired final concentration. DMSO present in the assay broth kept oleic acid in solution. Each MIC was obtained in duplicate. The MIC versus BSA concentration curve was plotted and subjected to linear regression analysis using SigmaPlot software (SPSS Inc., Chicago, IL). The increase in MIC in the presence of BSA was attributed to the association of the test compound with BSA, assuming that only free compound exhibits antibacterial activity. 7 The slope of the linear MIC versus BSA curve was calculated as
The increase in molar MIC of the test compounds was considered equal to its molar concentration bound to BSA. The slope was therefore used as an approximate measure of the compound (µM) bound per 1 µM of BSA, which was also the stoichiometry of compound:BSA association. The MIC of penicillin, tested in the presence of 0-12 µM BSA, remained unaffected by BSA.
Equilibrium dialysis was carried out in a double-sided Biodialyzer (The Nest Group, Inc., MA) following an established method. 8 Two chambers, both containing equal volumes (100-200 µL) and concentrations of buffer and the test inhibitor, and one containing 10 µM HSA, were used. The 2 chambers were separated by a semipermeable membrane allowing diffusion of mole-cules ≤ 10,000 Da. Overnight incubation at 37°C was carried out for diffusion to reach equilibrium. At equilibrium, absorbance in the visible range was used to measure inhibitor concentration in the 2 chambers and the HSA-binding affinity (K d ) and stoichiometry (n) were estimated.
RESULTS AND DISCUSSION
The MICs of the test compounds were plotted against the BSA concentration. The results, obtained with 2 selected compounds, are shown in Figure 1 . These data indicate a linear correlation between MIC and BSA concentration, with r 2 , the regression coefficient in the 0.9-1.0 range. The slope of the curves, used to estimate the approximate stoichiometry of the compound:BSA association, for PGE 6435616 and PGE 1744694 was 8.2 and 30, respectively. This suggests that these compounds could have multiple sites of association with BSA, and the number of sites of association could vary, presumably depending on the compound structure. Equilibrium dialysis experiments were conducted to further analyze the association between a number of compounds and HSA. The results obtained for 5 such compounds are shown in Figure 2 . Like the data on MIC in variable BSA, N, the stoichiometry for compound:HSA association, determined by the equilibrium dialysis method, suggests multiple binding sites. In addition, the equilib- rium dialysis data suggest that an increase in the compound:HSA molar ratio leads to an increase in the number (N) of compound molecules bound to each molecule of HSA at equilibrium. Potency of 69 compounds with MICs against S. aureus in the 3-200 µM range was tested in the presence of 0-12 µM (0-0.8 mg/ mL) BSA during this study. A linear relationship between BSA concentration and MIC was observed, with the linear regression coefficient (r 2 ) ≥ 0.9 for 49 compounds and > 0.5 for 62 compounds. As shown in Figure 3 , the slope for the linear correlation varied widely from 0.56 to 99.3 for these 62 compounds. For 3 compounds, designed in an effort to reduce the slope of the MIC-BSA curve, the MIC was either unchanged or within a range of 2fold increase in the presence of 0-12 µM BSA. Thus, the slope of the MIC-BSA curves for these compounds approached zero, suggesting that the BSA binding by these compounds was markedly reduced compared to other compounds tested during this study. However, these compounds still lost antibacterial activity in the presence of physiological serum albumin concentration. For 13 compounds with linear regression coefficients of the MIC-BSA curve in the 0.5-0.9 range, there was no obvious nonlinear trend in the shape of the curve and the relatively low regression coefficient is attributable to the noise in the MIC data. The same was true for compounds (n = 7) with linear regression coefficients of < 0.5.
To determine whether the loss of potency was due to a specific protein such as albumin, the potency of selected compounds was tested in the presence of 2 unrelated proteins, ALDH and TI, and also oleic acid, a nonprotein fatty acid. The results (Fig. 4) suggest that the effects of ALDH and oleic acid were similar to that of BSA at a comparable mass concentration range (0-0.4 mg/mL). However, presence of TI at this concentration range did not affect the potency of these compounds. TI is a hydrophilic protein predomi- nantly composed of β-strands and loops. These data suggest that the loss of potency of these compounds is attributable to their association with multiple, putatively nonspecific, hydrophobic sites. This notion is consistent with the apparently high stoichiometry of compound:BSA association, estimated from the slope of the MIC versus BSA curves, for many of the compounds tested. Although antibacterial compounds such as β-lactams are known to bind serum albumin, the consequent loss of activity and the stoichiometry of this binding is much lower, given its site-specific mechanism. 5 The wide compound-to-compound variation in the apparent stoichiometry of the compound:BSA association (discussed above) suggested that this effect was, at least in part, structurerelated. This raised the possibility that the slope of the MIC-BSA curve could be used as a tool to measure and minimize the compound:protein association effect during successive rounds of compound structure optimization. As discussed above, this approach succeeded in producing 3 compounds whose MICs did not increase due to BSA concentration in the 0-12 µM range.
CONCLUSION
The assay developed during this study measures an undesirable property that can be minimized through empirical strategies for compound design, while maintaining desired activity against the molecular and whole-cell target. This approach could also be used in estimating loss of target potency measured in terms of IC 50 due to the presence of a protein unrelated to the desired target and could therefore be broadly applicable as a secondary assay in a screening-based drug discovery program.
